Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
loteprednol (lotemax) (1 trial)
Dry Eye Syndromes (Phase 2)
Eye Diseases (Phase 2)
Keratoconjunctivitis (Phase 2)
Keratoconjunctivitis Sicca (Phase 2)
Trials (1 total)
Trial APIs (1 total)